Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer.

Autor: Ribeiro ARG; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Salvadori MM; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., de Brot L; Department of Pathology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Bovolin G; Department of Pathology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Mantoan H; Department of Gynecologic Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Ilelis F; Department of Pathology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Rezende M; Department of Pathology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., do Amaral NS; Department of Pathology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Sanches SM; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Maya JML; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Dos Santos ES; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Pereira R; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., de Souza Castro F; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., da Nogueira Silveira Lima JP; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Guimarães APG; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., Baiocchi G; Department of Gynecologic Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil., da Costa AABA; Department of Medical Oncology, AC Camargo Cancer Center, 211 Professor Antonio Prudente Street, Liberdade, São Paulo, SP 01509-900, Brazil.

Publikováno v: Ecancermedicalscience [Ecancermedicalscience] 2021 Jul 05; Vol. 15, pp. 1262. Date of Electronic Publication: 2021 Jul 05 (Print Publication: 2021).

Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma.

Autor: Alves MR; International Research Center, AC Camargo Cancer Center, São Paulo, Brazil., E Melo NC; Molecular Gynecology Laboratory, Gynecologic Department, Federal University of São Paulo, São Paulo, Brazil., Barros-Filho MC; International Research Center, AC Camargo Cancer Center, São Paulo, Brazil., do Amaral NS; International Research Center, AC Camargo Cancer Center, São Paulo, Brazil., Silva FIB; International Research Center, AC Camargo Cancer Center, São Paulo, Brazil., Baiocchi Neto G; Department of Gynecology Oncology, AC Camargo Cancer Center, São Paulo, Brazil., Soares FA; Department of Anatomic Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil., de Brot Andrade L; Department of Anatomic Pathology, A.C. Camargo Cancer Center, São Paulo, Brazil., Rocha RM; Molecular Gynecology Laboratory, Gynecologic Department, Federal University of São Paulo, São Paulo, Brazil.

Publikováno v: Cancer medicine [Cancer Med] 2018 Jul; Vol. 7 (7), pp. 3188-3199. Date of Electronic Publication: 2018 May 29.

Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections.

Autor: Fuentes-Mattei E; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Giza DE; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shimizu M; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ivan C; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The RNA Interference and Non-Coding RNA Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Manning JT; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, US., Tudor S; UMF Carol Davila Bucharest, Romania and Fundeni Hospital, Bucharest, Romania., Ciccone M; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Leukemia Department, Santa Anna Hospital, University of Ferrara, Ferrara, Italy., Kargin OA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Hacettepe University Faculty of Medicine, Ankara, Turkey., Zhang X; The RNA Interference and Non-Coding RNA Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mur P; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain., do Amaral NS; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Molecular Morphology Laboratory, AC Camargo Cancer Center, São Paulo 01508-010, Brazil., Chen M; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tarrand JJ; Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lupu F; Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA., Ferrajoli A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Keating MJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vasilescu C; UMF Carol Davila Bucharest, Romania and Fundeni Hospital, Bucharest, Romania., Yeung SJ; Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Calin GA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; The RNA Interference and Non-Coding RNA Center, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: gcalin@mdanderson.org.

Publikováno v: EBioMedicine [EBioMedicine] 2017 Jun; Vol. 20, pp. 182-192. Date of Electronic Publication: 2017 Apr 19.